


Close contacts of persons diagnosed with TB disease: What primary care providers need to know

Liz Lamere, MPH, RN – Maine CDC

Christina DeMatteo, DO, MPH - Infectious Disease,
Maine Medical Center Tuberculosis Clinic

Carol McCarthy, MD – Director of Pediatric Infectious Disease at
Maine Medical Center

December 4, 2023





Over the past 5 years, Maine has identified an average of 16 new cases of tuberculosis disease per year. In 2023 so far, we have identified **24 new cases***, representing a **50% increase in cases** over the 5-year average.

*data for 2023 are preliminary as of 11/30/23

Agenda


The goal of today's webinar is for providers in Maine to feel equipped to assess, evaluate, and treat contacts of TB disease.

- TB Epidemiology
- Maine CDC role in tuberculosis disease and latent tuberculosis infection care
- Assessing adult contacts
- Assessing pediatric contacts
- Questions

Terminology


- **TB Disease:** Infection with *Mycobacterium tuberculosis*. Symptomatic, infectious; most often pulmonary but can occur in any part of the body. Also called “active TB”.
- **Latent Tuberculosis Infection (LTBI):** Infection with *Mycobacterium tuberculosis*. Asymptomatic, noninfectious, can develop into TB disease.

To date, Maine has identified **24 new cases of TB disease** in 2023*.




*data for 2023 are preliminary as of 11/30/23

The rate of TB disease per 100,000 has also increased in Maine this year*




*data for 2023 are preliminary as of 11/30/23

Though Maine's rate is still below the U.S. rate of TB disease per 100,000




*data for 2023 are preliminary as of 11/30/23

Persons with TB disease were diagnosed in 6 counties in Maine in 2023*



*data for 2023 are preliminary as of 11/30/23

Most TB in Maine is pulmonary TB*




*data for 2023 are preliminary as of 11/30/23

Maine CDC Role in TB Investigations

- TB disease
 - Reportable Condition
- Maine CDC investigates all cases of TB
 - Conducts contact investigations, as appropriate
 - Assists with payment for treatment
 - Helps remove barriers that impede treatment adherence

Confirmed TB Disease

- Receive test results from lab
- Inform IP/provider
- Coordinate with pharmacy and manage payments
- Refer to PHN for directly observed therapy (DOT)
 - Required for all pulmonary patients
 - Requested for extrapulmonary patients
 - Providers not requesting DOT are responsible for their patient's compliance
- Case management
- Contact investigations



Key Terms

- Case – A particular instance of a TB disease. A case is detected, documented, and reported.
- Contact – Someone who has been exposed to *M. tuberculosis* by sharing air space with a person with TB disease during their infectious period.

Determining the Infectious Period

- Focuses investigation on contacts most likely to be at risk for infection
- Sets time frame for testing contacts
- Information to assist with determining infectious period
 - Approximate dates TB symptoms were noticed
 - Bacteriologic results
 - Extent of disease

Estimating the Beginning of the Infectious Period

Characteristic of Index Case				
TB symptoms	AFB sputum smear positive	Cavitary chest radiograph		Likely period of infectiousness
Yes	No	No		3 months before symptom onset or 1 st positive finding consistent with TB disease, whichever is longer
Yes	Yes	Yes		3 months before symptom onset or 1 st positive finding consistent with TB disease, whichever is longer
No	No	No		4 weeks before date of suspected diagnosis
No	Yes	Yes		3 months before positive finding consistent with TB

SOURCE: California Department of Health Services Tuberculosis Control Branch; California Tuberculosis Controllers Association. Contact Investigation Guidelines. Berkley, CA: California Department of Health Services; 1998.

Infectious Period Estimate for a Smear Positive Case with TB Symptoms

The infectious period starts 3 months before symptom onset and ends the date that the case meets all of the criteria for ending the infectious period (August 1st to December 1st)

Effective treatment for 2 weeks or longer; diminished symptoms; and mycobacteriologic response; end of infectious period

3 months before symptom onset; start of infectious period

Treatment started Nov. 15th

Symptom onset

1-Jun

1-Jul


1-Aug

1-Sep

1-Oct

1-Nov

1-Dec




Factors that Predict Transmission of TB

- Anatomical site of the disease (pulmonary or laryngeal)
- Positive sputum bacteriology
- Radiographic findings (cavitary disease)
- Behaviors that increase aerosolization of respiratory secretions (singing, sociability)
- Age (transmission from children <10 is unusual)
- HIV infection
- Administration of effective treatment

Close Contact Identification


- Close contacts are persons who have shared airspace (within 6 feet) with a person with TB disease during their infectious period for a cumulative 8 or more hours.
- These persons may include household members, friends, coworkers, classmates, and others.



Contact Investigation – A Crucial Prevention Strategy

- On average, 10 contacts are identified for each person with TB disease in the U.S.
- 20%–30% of all contacts have LTBI
- 1% of contacts have TB disease
- Of contacts who will ultimately have TB disease, approximately one-half develop disease in the first year after exposure


Average TB contact investigations identify 10 contacts



 Average # of contacts

Selected Results of Contact Investigations, Maine 2023*

*data for 2023 are preliminary as of 11/30/23




 Average # of contacts

 Maine investigations below 10 contacts

In 2023, 8 contact investigations in Maine have identified over the average of 10 contacts*

*data for 2023 are preliminary as of 11/30/23



Average # of contacts

Maine investigations below 10 contacts

Maine investigations above 10 contacts

Contact Investigation Roles

- **Maine CDC:**
 - **Public Health Nurses:** perform contact investigations for smaller investigations, plant and read tuberculin skin test, connect contacts to care when evaluation is needed
 - **TB Control/epidemiology:** oversees contact investigations and assists in larger contact investigations, provide exposure letter for large investigations, collaborates with healthcare partners to provide education and consultation, works with organizations lead/contact to track test results of contact, provide up-to-date recommendations for providers (i.e. drug resistance)
- **Organizational lead/contact** (i.e., school nurse, HR rep, infection preventionist): identifies contacts in larger investigations, distributes exposure letter to contacts
- **Primary Care Providers:** evaluate contacts for *M. tuberculosis* infection and TB disease, administer treatment for LTBI
- **TB Consultants:** Provide expert consultation as needed, care for patients with TB disease

Maine CDC can pay for costs associated with screening close contacts and LTBI treatment.

- For costs associated with screening close contacts who are uninsured or underinsured, please contact Maine CDC at 1-800-821-5821.
- For costs associated for LTBI treatment, the treating provider should fill out Maine CDC's LTBI referral form and send to Maine CDC.

Reporting TB Disease to Maine CDC

- **TB Disease:** Reportable immediately upon suspicion or confirmation calling 1-800-821-5821.
- **LTBI** is not reportable
- For TST/IGRA results related to contact investigations, Maine CDC would like to receive results by electronic laboratory reporting, fax 1-800-293-7534, or by calling 1-800-821-5821.

Resources and References

- [Maine CDC health advisory: Think. Test. Treat Tuberculosis \(TB\) in Maine](#) (March 24, 2023)
- Maine CDC LTBI Treatment Referral <https://www.maine.gov/dhhs/mecdc/infectious-disease/epi/tuberculosis/documents/LTBI-Treatment-Referral.pdf>
- Maine CDC TB resources for Healthcare Providers <https://www.maine.gov/dhhs/mecdc/infectious-disease/epi/tuberculosis/health-care.shtml>
- Webinar: Latent Tuberculosis for the Primary Care Clinician (Northern Light Health in collaboration with Maine CDC): <https://www.youtube.com/watch?v=LAYFpqLbHY>
- U.S. CDC Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis <https://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf>
- U.S. CDC Treatment Regimens for Latent TB Infection <https://www.cdc.gov/tb/topic/treatment/ltbi.htm>
- U.S. CDC Latent Tuberculosis Infection: a guide for primary health <https://www.cdc.gov/tb/publications/ltbi/pdf/LTBIbooklet508.pdf>
- U.S. CDC Deciding When to Treat Latent TB Infection <https://www.cdc.gov/tb/topic/treatment/decidelatbi.htm>
- U.S. CDC Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 https://www.cdc.gov/mmwr/volumes/69/rr/rr6901a1.htm?s_cid=rr6901a1_w
- U.S. CDC Tuberculin Skin Testing Fact Sheet <https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm>
- Extrapulmonary tuberculosis: an old but resurgent problem. <https://pubmed.ncbi.nlm.nih.gov/35254534/>
- US CDC Core Curriculum on Tuberculosis: what the clinician should know <https://www.cdc.gov/tb/education/corecurr/index.htm>
- QuantiFERON-TB Gold+ for the Diagnosis of Mycobacterium tuberculosis Infection. <https://www.aafp.org/pubs/afp/issues/2021/0201/p177.html>

Questions?

**For a list of Maine
CDC and U.S. CDC
resources, scan
here:**

